---
document_datetime: 2025-09-03 15:42:36
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/enzalutamide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: enzalutamide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7737572
conversion_datetime: 2025-12-29 22:39:52.355109
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Enzalutamide Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1 Change in the shelf-life or storage | 28/08/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000289520      | conditions of the finished product - B.II.f.1.z To increase the shelf-life in accordance with ICH guidelines and amend storage conditions (e.g. decrease in temperature to preserve longer shelf-life) - Accepted                                                                                                                                                                                                                                                                                                                                                                                |            |             |                   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------|
| Variation type IA_IN / | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - Accepted                                                                                                                                                                                                                                                      | 25/08/2025 | SmPC        | EMA/VR/0000293010 |
| Variation type IB /    | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.2, 4.4 and 4.8 of the SmPC to add a new warning on Dysphagia and to add dysphagia to the list of adverse drug reactions (ADRs) with frequency Not known, and to add decreased appetite to the list of adverse drug reactions | 23/05/2025 | SmPC and PL | EMA/VR/0000269129 |

<div style=\"page-break-after: always\"></div>

| (ADRs) with frequency Not known. The PL is updated accordingly. The changes follow assessment of the same changes for the reference product Xtandi. In addition, the MAH took the opportunity to update the PI with editorial changes to align with the QRD template, including the removal of the local representative for the UK. Furthermore, the MAH took the opportunity to implement editorial changes to the PI for DE, EL, HU, NL and SL, to align with the PI of the reference product and the QRD template.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|